araag2/HINT huggingface dataset:
Clinical trial NCT01857583 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: 15mg du-176b, 30mg du-176b, fondaparinux
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs

        Exclusion Criteria:

          -  Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the
             study period

          -  Patients who are at a significantly high risk for bleeding or thromboembolism

          -  Patients who are receiving another antithrombotic therapy and are unable to suspend
             the therapy

          -  Patients who have evidence of hepatic function test abnormalities
Clinical trial NCT02658188 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: asp8825
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who diagnosed with RLS according to the diagnostic criteria established by
             the International RLS Study Group

          -  International Restless Legs Syndrome Scale (IRLS) score ≥15 presence of RLS symptoms
             on ≥15 days per month and ≥4 days per week preceding inclusion in this study

        Exclusion Criteria:

          -  Patients using dopamine agonists or gabapentin within 1 week before or any anti-RLS
             treatment within 2 weeks before the start of the pretreatment observation period

          -  Patients with an estimated creatinine clearance <60 mL/min determined using the
             Cockcroft-Gault formula

          -  Pregnant or lactating women

          -  Individuals with serum ferritin <20 ng/mL were also excluded from the trial

          -  Individuals with movement disorders and/or abnormal neurological findings
Clinical trial NCT00430742 (phase 3, status: terminated)
Conditions: obesity type 2 diabetes mellitus, type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: taranabant, comparator: placebo
SMILES: C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN(C)C(=N)NC(N)=N
Reason stopped: 
    the overall profile does not support development for obesity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Body Mass Index (BMI) between 27 kg/m2 and 43 kg/m2 and HbA1c between 7.0% and 10%

        Exclusion Criteria:

          -  History of major psychiatric disorder

          -  Blood pressure greater than 160/100

          -  Use of any antihyperglycemic agent other than metformin

          -  Triglycerides greater then 600 mg/dL
Clinical trial NCT01170663 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: placebo, paclitaxel
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  histologically or cytologically confirmed gastric or gastroesophageal junction
             adenocarcinoma

          -  Metastatic disease or locally advanced, unresectable disease

          -  Disease progression during or within 4 months after the last dose of the first-line
             therapy (platinum/fluoropyrimidine doublet with or without anthracycline)

          -  Organs are functioning well (liver, kidney, blood)

          -  Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status
             (PS) 0 to 1

        Exclusion Criteria:

          -  First line chemotherapy for metastatic gastric cancer other than
             platinum/fluoropyrimidine doublet with or without anthracycline

          -  Previous systemic therapy with other anti-angiogenic drugs

          -  Uncontrolled high blood pressure

          -  Symptomatic or poorly controlled heart disease or had a heart attack or stroke within
             the last 6 month

          -  Evidence of central nervous system (CNS) metastasis at baseline
Clinical trial NCT00410410 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: abatacept (aba), placebo, abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women 18 years or older

          -  Ulcerative colitis for at lease 3 months

          -  Moderate to severe active ulcerative colitis

          -  Inadequate response or intolerance to standard ulcerative colitis treatment
Clinical trial NCT00211133 (phase 3, status: completed)
Conditions: anemia, breast neoplasms, quality of life
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients >= 18 years of age with confirmed diagnosis of metastatic breast
             cancer who are predicted to start chemotherapy for the first time

          -  Weight > = 40 kg (88 lbs)

          -  Postmenopausal for at least 1 year, surgically sterile or practicing an effective
             method of birth control and have a negative serum pregnancy test at the start of the
             study

          -  Must have signed an informed consent

        Exclusion Criteria:

          -  Clinically significant lung, heart, hormone, neurological, gastrointestinal, urinary
             tract or reproductive system disease

          -  Receiving dose intensification chemotherapy for bone marrow or stem cell
             transplantation

          -  Cancer of the brain or brain/spinal cord disease

          -  Locally advanced or inflammatory breast cancer as the only symptom of breast cancer

          -  Active second primary cancer or documented history of other cancer within the last 3
             years

          -  Anemia from a cause other than cancer or radiotherapy/chemotherapy

          -  History of stoke, clots in the lungs or legs or any other blood clotting disorders

          -  Uncontrolled high blood pressure

          -  Untreated folate or Vitamin B12 deficiency

          -  Treatment with epoetin alfa or other forms of erythropoietin within the last 4 weeks

          -  Known hypersensitivity to epoetin alfa or any of its components

          -  Pregnant or breast-feeding
Clinical trial NCT00227305 (phase 3, status: completed)
Conditions: schizophrenia, bipolar i disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is able to provide written assent and the parents or legal guardian of the
             patient are/is able to provide written informed consent before beginning any study
             related procedures

          -  Patient previously enrolled in either double-blind Study D1441C00149 or D1441C00112

          -  Patient has documented clinical diagnosis of schizophrenia or bipolar I disorder

          -  Patient's parent or legal guardian will be able to accompany the patient to each
             scheduled study visit

        Exclusion Criteria:

          -  Patients (female) must not be pregnant or lactating

          -  Patients with a known intolerance or lack of response to previous treatment with
             quetiapine

          -  Patients who have previously participated in this study
Clinical trial NCT00452166 (phase 3, status: terminated)
Conditions: chronic kidney disease, insulin resistance
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, Z16.11, Z16.21, D68.51, Z16.20, Z16.24, Z16.22, Z16.23
Drugs: rosiglitazone
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Reason stopped: 
    it was not possible to recruit new patients anymore
  
Eligibility criteria:

        Inclusion Criteria:

          -  CKD stage 4

          -  BMI ≤ 30

          -  Fasting glucose < 7 mmol/l

        Exclusion Criteria:

        Exclusion of patients will take place in case of:

          -  A diagnosis of diabetes mellitus for which the patient uses insulin

          -  Significant co-morbidities which, according to the treating nephrologists, makes it
             unlikely that the patient will be able to complete the foreseen study period

          -  Significant cardiovascular co-morbidities which are likely to interfere with the
             objectives of the study (morbid obesity, family history of dyslipidemia, etc.); at the
             discretion of the treating nephrologists or the principal investigator

          -  Allergy for PPAR's

          -  Cardiac disease with marked limitation of functional capacity (New York Heart
             Association III or IV clinical status)

          -  Use of immunosuppressant agents

          -  History of renal transplant

          -  Hepatic insufficiency (defined as transaminase concentrations above > 2.5 times the
             upper limit of normal for the laboratories)

          -  A history of alcohol abuse or excessive alcohol use defined as more than 21
             consumptions per week

          -  For female patients: pregnancy, the intention to become pregnant within the study
             period, or lactating patients
Clinical trial NCT01104766 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: cariprazine, aripiprazole, placebo
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have provided informed consent prior to any study specific procedures

          -  Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
             disorganized type, catatonic type or undifferentiated type), as confirmed by the
             Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (SCID)

          -  Patients with normal physical examination, laboratory, vital signs,and/ or
             electrocardiogram (ECG)

          -  Current psychotic episode (schizophrenia exacerbation) < 2 weeks duration at Visit 1

          -  Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS)
             total score ≥ 80 and ≤ 120

          -  CGI-S score ≥ 4

        Exclusion Criteria:

          -  Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders

          -  Bipolar I and II disorder

          -  Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and
             other cognitive disorders

          -  DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in
             this study

          -  Women who are pregnant or breast feeding
Clinical trial NCT01038739 (phase 3, status: terminated)
Conditions: diverticulitis
ICD codes: K57.00, K57.01, K57.12, K57.13, K57.20, K57.21, K57.32
Drugs: mesalazine, mesalazine, placebo
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    stopped due to futility.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of left-sided uncomplicated diverticular disease confirmed by computed
             tomography

          -  Presence of at least one diverticulum of the left colon

          -  Most recent attack of left-sided uncomplicated diverticulitis responding to
             antibiotics and/or dietary modification within the last 6 months

          -  C-reactive protein (CRP) > upper limit of normal (ULN) or leucocytosis at the start of
             the most recent attack

        Exclusion Criteria:

          -  Complicated diverticular disease

          -  Right-sided diverticulitis

          -  Previous colonic surgery

          -  Presence of symptomatic organic disease of the gastrointestinal tract

          -  Active colorectal cancer or a history of colorectal cancer

          -  Hemorrhagic diathesis

          -  Active peptic ulcer disease, local intestinal infection

          -  Asthma if careful medical monitoring is not ensured

          -  Abnormal hepatic function or liver cirrhosis

          -  Abnormal renal function
Clinical trial NCT00737568 (phase 3, status: completed)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: tdf, ftc/tdf, tdf placebo, ftc/tdf placebo
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria

          -  Chronic HBV infection, defined as positive serum HBsAg for at least 6 months

          -  18 through 75 years of age, inclusive

          -  HBV DNA ≥ 10^3 IU/mL

          -  Receiving treatment with lamivudine with confirmation of HBV reverse transcriptase
             mutation(s) known to confer resistance to lamivudine (rtM204I/V with or without
             rtL180M) by central laboratory assessment prior to randomization; adefovir dipivoxil
             treatment of ≤ 48 weeks at the time of screening (inclusive of combination adefovir
             dipivoxil + lamivudine at entry) was allowed

          -  Willing and able to provide written informed consent

          -  Negative serum pregnancy test (for females of childbearing potential only)

          -  Calculated creatinine clearance ≥ 50 mL/min

          -  Hemoglobin ≥ 10 g/dL

          -  Neutrophils ≥ 1000 /mm^3

          -  No prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other
             investigational agents for HBV infection other than lamivudine or adefovir dipivoxil

        Exclusion Criteria

          -  Pregnant women, women who are breast feeding or who believe they may wish to become
             pregnant during the course of the study

          -  Males and females of reproductive potential who are not willing to use an effective
             method of contraception during the study

          -  Alanine aminotransferase (ALT) ≥ 10 × the upper limit of the normal range (ULN)

          -  Decompensated liver disease

          -  Interferon or pegylated interferon therapy within 6 months of the screening visit

          -  Alpha fetoprotein > 50 ng/mL

          -  Evidence of hepatocellular carcinoma

          -  Coinfection with hepatitis C virus, HIV, or hepatitis D virus

          -  Significant renal, cardiovascular, pulmonary, or neurological disease

          -  Received solid organ or bone marrow transplantation

          -  Receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational
             agents, nephrotoxic agents, or agents susceptible of modifying renal excretion

          -  Proximal tubulopathy

          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients
Clinical trial NCT00395070 (phase 3, status: completed)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: dacarbazine (dtic), temozolomide (tmz)
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O, CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria (Potential study participants must meet the following criteria):

          -  Confirmed Stage 3 or Stage 4 melanoma that may have had previous treatment via
             surgery, radiation or biologic drugs (typically Interferon Alpha or Interleukin-2)

          -  At least 1 melanoma tumor that is 1cm x 1cm or greater in size (about the size of a
             dime) and can be injected

          -  Normal blood chemistries and blood cell counts

          -  At least 18 years old and able and willing to provide informed consent to participate

        Exclusion Criteria (Potential study participants will not be eligible with the following):

          -  Previous chemotherapy treatment for melanoma

          -  Melanoma lesions in the brain or liver (however, lesions in the lungs are allowed)

          -  If surgical removal of all lesions would be possible and could be curative

          -  Any melanoma tumors greater than 10cm x 10cm in size

          -  Known condition resulting in a suppressed immune system

          -  Female subjects who are pregnant
Clinical trial NCT01183442 (phase 3, status: terminated)
Conditions: coronary artery disease, postprandial hyperglycemia, vitamin d deficiency
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, E55.9, D51.0, D51.1, D51.3, D51.8, D51.9, E50.0
Drugs: vitamin d
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Reason stopped: 
    unable to recruit
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 40-75

          -  Postchallenge hyperglycemia (2h-whole blood glucose value in oral glucose tolerance
             test above 119 mg/dl, normal fasting glucose)

          -  Angiographically verified coronary artery disease (>50% stenosis)

          -  Serum 25-OH- vitamin D < 20 ng/ml in winter/spring/autumn and <25 ng/ml during
             june-september

          -  Stable antihypertensive therapy in the last 3 month

        Exclusion Criteria:

          -  Acute coronary syndrome or cerebrovascular event within the previous 1 month

          -  BMI > 40 kg/m²

          -  Serum creatinine >2.5 times the upper limit of normal

          -  GOT or GPT > 3 times the upper limit of normal

          -  Heart failure > NYHA class II

          -  Uncontrolled hypertension (>160/100 mmHg)

          -  New onset of statins, ACE-inhibitors or ARBs within the previous 4 weeks

          -  History of urolithiasis

          -  Hypercalcaemia

          -  Major psychiatric disorders

          -  Ongoing treatment with spironolactone, canrenoate, eplerenone, amiloride, triamterene
             and aliskiren.

          -  Treatment with antipsychotic drugs

          -  Regular significant antioxidants, vitamins or protein supplementation

          -  Immunosuppressive therapy

          -  Glucocorticoid therapy

          -  Ongoing chemotherapy

          -  Pregnancy

          -  Any other disease with an estimated life expectancy below 1 year.
Clinical trial NCT00253968 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders, insomnia
ICD codes: Y93.E9, Y93.H9, F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: eplivanserin, placebo
SMILES: CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)/C1=CC=CC=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Out patients

          -  Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I
             (Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition-Text Revision)
             criteria

          -  Based on patient's information, the patient must complain of at least one hour of
             wakefulness after sleep onset for at least 3 nights per week over the preceding month

          -  Patient must report impact daytime functioning associated with sleep maintenance
             insomnia as measured by question 3 of Insomnia Severity Index at screening visit and
             randomization visit.

        Exclusion Criteria:

          -  Females who are lactating or pregnant

          -  Woman of childbearing potential with a positive serum beta human chorionic
             gonadotropin pregnancy test at screening and not using an acceptable form of
             contraception

          -  Patients presenting with acute or chronic pain resulting in insomnia

          -  Patients with history of epilepsy or seizures

          -  Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising
             more than 5 glasses/day

          -  Evidence of any clinically significant, severe, or unstable acute or chronically
             progressive medical or surgical disorder which may affect patient safety

          -  BMI >32

          -  Acute or chronic pain resulting in insomnia

          -  Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental
             retardation, or dementia

          -  Clinically significant and abnormal EKG (QTc interval >=500 msec)

          -  Positive for hepatitis B or C

          -  Serious head injury or stroke within 1 year

          -  Use of OTC (over-the-counter) medications such as valerian root, kava, melatonin, St.
             John's Wort, or alluna; prescription sleep medications or anxiolytics within 1 week or
             5 half-lives

          -  Participation in another trial within two month before the screening visit

          -  Use of any substance with psychotropic effects or properties known to affect
             sleep/wake

          -  Unable to complete the study questionnaires

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  History of:

               -  Primary hypersomnia

               -  Narcolepsy

               -  Breathing-related sleep disorder (such as sleep apnea)

               -  Circadian rhythm sleep disorder

               -  Parasomnia (somnambulism)

               -  Dyssomnia (such as periodic leg movements)
Clinical trial NCT01857063 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: montelukast, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Weight: ≥ 25 kg

          -  Height: ≥ 125 cm

          -  Able to record symptoms in a diary

          -  Has had allergic rhinitis symptoms [Japanese Cedar (JC) pollinosis]

          -  Tested positive for JC pollen specific immunoglobulin E (IgE) antibody assay

        Exclusion Criteria:

          -  Has nasal findings that would interfere with evaluating nasal congestion symptoms

          -  Past or present medical history of bronchial asthma

          -  Medical history of allergies except allergic rhinitis and has possibility of
             dramatically worsening of these symptoms induced by JC pollen exposure